Therapeutic Action
Antiseizure (anticonvulsant)
Source page 477
Loading InternPractice…
Individual generic drug information
Extracted information for PHENYTOIN only.
Antiseizure (anticonvulsant)
Source page 477
Second-line treatment of convulsive status epilepticus
Source page 477
Extracted information for PHENYTOIN only.
Do not administer to patients with bradycardia or atrioventricular block. Administer with caution in patients with hepatic impairment (reduce dosage), heart failure, cardiac rhythm disorders, hypotension. May cause: irritation or swelling at injection site; necrosis in the event of extravasation; drowsiness, dizziness, headache, behavioural disturbances; hypotension, bradycardia, conduction disorders, when injected too rapidly; gastrointestinal disturbances (nausea, vomiting), hepatotoxicity; haematologic disorders and hypersensitivity reactions sometimes severe; cardiac complications and coma in the event of overdose. Closely monitor heart rate and blood pressure during and after administration. Reduce the infusion rate in the event of bradycardia or drop in blood pressure. Avoid IV placement in the hand, foot or wrist. Closely monitor injection site, during and after administration, in particular in: older or very young patients (fragile veins), patients with cardiovascular disease. Before and after infusion, flush the catheter with 0.9% NaCl to limit venous irritation and potential incompatibility with other drugs. Avoid or monitor the combination with: rifampicin, mefloquine (reduced effect of PHT); sulfonamides, chloramphenicol, fluconazole, isoniazid, fluoxetine, omeprazole (increased PHT toxicity); benzodiazepines, opioid analgesics, antipsychotics, first-generation antihistamines (hydroxyzine, promethazine), antidepressants, other antiseizure medications, etc. (increased sedation). PHT may reduce the effect of many drugs: diazepam, midazolam, digoxin, corticosteroids, antimicrobials, some antiretrovirals, itraconazole, warfarin, etc. Adjust dosage if necessary. implants and oral contraceptives: use condoms until next menstruation. Pregnancy and breast-feeding: prefer a safer drug (levetiracetam). If PHT is the only option, the risks linked to status epilepticus appear greater than risks linked to PHT.
Source pages 478, 479
Extracted information for PHENYTOIN only.
250 mg in 5 ml ampoule or vial (50 mg/ml), for IV route only, to be administered through a large central or peripheral vein. Dilute the solution in 0.9% sodium chloride only. DO NOT DILUTE IN GLUCOSE. For administration use a infusion set or line with a 0.2 micron filter. DO NOT ADMINISTER BY RAPID IV INJECTION.
Source page 477
Loading dose: Child and adult: 20 mg/kg (max. 2 g) single dose Patients Mode of administration Duration of infusion Max. rate Children ≥ 1 month Use diluted solution: add 1 ml 20 min 1 mg/kg/min and ≤ 25 kg (50 mg) of PHT to 9 ml of 0.9% NaCl to obtain 10 ml of solution containing 5 mg of PHT per ml. Administer by IV infusion using a (a) syringe pump . Children > 25 kg Add undiluted solution to a 100 ml ≤ 1 g or ≤ 50 kg: 20 min 50 mg/min and adults bag of 0.9% NaCl. Administer by IV infusion. > 1 g and ≤ 1.5 g or > 50 kg and ≤ 75 kg: 30 min > 1.5 g and ≤ 2 g or > 75 kg and ≤ 100 kg: 40 min Older patients Add undiluted solution to a 100 ml ≤ 1 g or ≤ 50 kg: 40 min 25 mg/min (≥ 65 years) bag of 0.9% NaCl. Administer by and adults with IV infusion. > 1 g and ≤ 1.5 g or > 50 cardiac disorders kg and ≤ 75 kg: 60 min > 1.5 g and ≤ 2 g or > 75 kg and ≤ 100 kg: 80 min a Or only if syringe pump is not available, use a paediatric infusion set. If maintenance treatment is indicated after the loading dose: change to oral route as soon as possible.
Source pages 477, 478
Extracted information for PHENYTOIN only.
Do not mix with other drugs in the same syringe or infusion.
Source page 479
– Below 25 °C
Source page 479
Filter the extracted dose blocks for this individual drug.
20 mg/kg (max. 2 g) single dose
Candidate age grouping · source page 477